Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 3
2022 6
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
The TKI Era in Chronic Leukemias.
De Novellis D, Cacace F, Caprioli V, Wierda WG, Mahadeo KM, Tambaro FP. De Novellis D, et al. Pharmaceutics. 2021 Dec 20;13(12):2201. doi: 10.3390/pharmaceutics13122201. Pharmaceutics. 2021. PMID: 34959482 Free PMC article. Review.
High-Risk Acute Myeloid Leukemia: A Pediatric Prospective.
Cacace F, Iula R, De Novellis D, Caprioli V, D'Amico MR, De Simone G, Cuccurullo R, Wierda WG, Mahadeo KM, Menna G, Tambaro FP. Cacace F, et al. Among authors: de novellis d. Biomedicines. 2022 Jun 14;10(6):1405. doi: 10.3390/biomedicines10061405. Biomedicines. 2022. PMID: 35740427 Free PMC article. Review.
Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
Giudice V, Serio B, Errichiello S, Ferrara I, Galdiero A, Bertolini A, Visconti R, De Novellis D, Guariglia R, Luponio S, Morini D, Della Corte AM, Sessa AM, Verdesca F, Langella M, Izzo B, Selleri C. Giudice V, et al. Among authors: de novellis d. Eur J Haematol. 2023 Nov;111(5):729-741. doi: 10.1111/ejh.14069. Epub 2023 Jul 27. Eur J Haematol. 2023. PMID: 37501402
Safety of Subcutaneous Daratumumab in Anti-CD38 Monoclonal Antibody-Naïve Patients with Plasma Cell Disorders: A Multicenter Real-Life Experience.
De Novellis D, Fontana R, Palmieri S, Della Pepa R, Di Perna M, Cetani G, Esposito D, Amendola A, Delle Cave G, Serio B, Morini D, Rizzo M, Mettivier L, Trastulli F, Rocco S, Pagano A, Barbato S, Leone A, La Magna M, Bianco R, Rascato G, Carobene A, Cuffa B, Iannalfo M, Giudice V, Svanera G, Annunziata M, Pizzuti M, Frigeri F, Califano C, Ferrara F, Pane F, Selleri C. De Novellis D, et al. Target Oncol. 2023 Nov;18(6):885-892. doi: 10.1007/s11523-023-01001-4. Epub 2023 Sep 25. Target Oncol. 2023. PMID: 37747623 Free PMC article.
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.
Iula R, De Novellis D, Trastulli F, Della Pepa R, Fontana R, Carobene A, Di Perna M, D'Ambrosio A, Romano M, Leone A, De Fazio L, Fiumarella A, Gaeta G, Marafioti V, Barbato S, Palmieri S, Rocco S, Serio B, Califano C, Pane F, Ferrara F, Giudice V, Selleri C, Catalano L. Iula R, et al. Among authors: de novellis d. Front Oncol. 2022 Nov 15;12:1026251. doi: 10.3389/fonc.2022.1026251. eCollection 2022. Front Oncol. 2022. PMID: 36457484 Free PMC article.
18 results